Insider Selling: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Sells 125,000 Shares of Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Jack A. Khattar sold 125,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total value of $4,585,000.00. Following the sale, the chief executive officer now directly owns 926,172 shares of the company’s stock, valued at $33,971,988.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock traded up $0.20 during mid-day trading on Friday, hitting $36.60. 578,615 shares of the company were exchanged, compared to its average volume of 452,714. Supernus Pharmaceuticals, Inc. has a 12-month low of $24.46 and a 12-month high of $39.37. The business’s 50 day simple moving average is $33.11 and its two-hundred day simple moving average is $30.63. The company has a market capitalization of $2.02 billion, a P/E ratio of 34.02 and a beta of 0.86.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The firm had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. During the same quarter in the previous year, the business earned ($0.29) earnings per share. The firm’s quarterly revenue was up 14.2% compared to the same quarter last year. Equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.53 earnings per share for the current year.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of SUPN. Commonwealth Equity Services LLC lifted its stake in shares of Supernus Pharmaceuticals by 3.6% in the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company’s stock worth $273,000 after acquiring an additional 350 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after acquiring an additional 352 shares in the last quarter. Covestor Ltd raised its stake in Supernus Pharmaceuticals by 15.3% during the first quarter. Covestor Ltd now owns 2,702 shares of the specialty pharmaceutical company’s stock valued at $92,000 after buying an additional 358 shares in the last quarter. GAMMA Investing LLC raised its stake in Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 398 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its stake in Supernus Pharmaceuticals by 2.2% during the second quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company’s stock valued at $741,000 after buying an additional 600 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts have weighed in on SUPN shares. Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.